Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia-Reference-Cited by-同舟云学术

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

Published:2016-03-03 Issue:9 Volume:127 Page:1117-1127
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Fraietta Joseph A.¹²^ORCID,Beckwith Kyle A.³,Patel Prachi R.¹²,Ruella Marco¹²^ORCID,Zheng Zhaohui¹²,Barrett David M.⁴^ORCID,Lacey Simon F.¹²^ORCID,Melenhorst Jan Joseph¹²^ORCID,McGettigan Shannon E.¹²,Cook Danielle R.¹²,Zhang Changfeng¹²^ORCID,Xu Jun¹²,Do Priscilla³,Hulitt Jessica⁴,Kudchodkar Sagar B.¹²,Cogdill Alexandria P.¹²,Gill Saar¹⁵^ORCID,Porter David L.¹²⁵^ORCID,Woyach Jennifer A.³,Long Meixiao³^ORCID,Johnson Amy J.³,Maddocks Kami³,Muthusamy Natarajan³,Levine Bruce L.¹²⁶^ORCID,June Carl H.¹²⁶^ORCID,Byrd John C.³,Maus Marcela V.⁷^ORCID

Affiliation:

1. Center for Cellular Immunotherapies and

2. Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA;

3. Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH;

4. Division of Oncology, Children’s Hospital of Philadelphia, Philadelphia, PA;

5. Division of Hematology-Oncology, Department of Internal Medicine and

6. Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA; and

7. Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA

Abstract

Key Points Ibrutinib treatment of CLL enhances the generation of CAR T cells for adoptive immunotherapy. Concurrent ibrutinib therapy improves the engraftment and therapeutic efficacy of anti-CD19 CAR T cells in mouse models.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/127/9/1117/1395722/1117.pdf

Reference50 articles.

1. The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors.;Rossi;Br J Haematol,2009

2. Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls.;Moreira;Leukemia,2013

3. A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia.;D’Arena;Am J Hematol,2012

4. Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease.;D’Arena;Leuk Res,2011

5. Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia.;Palmer;Br J Haematol,2008

Cited by 388 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chimeric antigen receptor T‐cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice;British Journal of Haematology;2024-09-11

2. Targeting chronic lymphocytic leukemia with B‐cell activating factor receptor CAR T cells;MedComm;2024-09

3. Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features;Cellular Oncology;2024-08-27

4. iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens;Frontiers in Oncology;2024-08-26

5. Targeting the tumor microenvironment for treating double-refractory chronic lymphocytic leukemia;Blood;2024-08-08